HEPATOBILITY

Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study

M Wright¹, R Goldin¹, A Fabre¹, J Lloyd¹, H Thomas¹, C Trepo², P Pradat², M Thursz¹ On Behalf Of The Hencore Collaboration

¹ Hepatology Section, Faculty of Medicine, Imperial College, London W2 1NY, UK
² Department of Gastroenterology, Hotel-Dieu, 1 Place de l’Hopital, F-69288 Lyon, Cedex 02, France

Correspondence to:
Correspondence to:
Dr M Wright, Department of Medicine, Imperial College of Science, Technology, and Medicine, St Mary’s Hospital (QEQM Wing), South Wharf Road, London W2 1NY, UK;
mark.wright{at}ic.ac.uk

Introduction: The rate of development of liver fibrosis in hepatitis C virus (HCV) infection varies between individuals. This accounts for the variation in duration of progression to cirrhosis. The aims of this study were: (1) to determine whether fibrosis progresses linearly through the grading scales and (2) to identify factors which influence the rate of fibrosis.

Methods: HCV infected patients who had undergone at least one liver biopsy were identified. Biopsies were scored using the modified HAI (Ishak) and METAVIR systems, which were compared. Patients were treatment naïve at first biopsy. Demographic features were examined for their relationship to fibrosis rate (defined as fibrosis stage/infection duration) using univariate and multivariate analysis. A subgroup of patients with two biopsies was examined to test the assumption that fibrosis progresses in a linear fashion.

Results: A total of 917 patients were included. Male sex (p<0.00001), older age at infection (p0.00001), and viral genotype non-1 (p=0.005) were all associated with a rapid rate of fibrosis. On multiple linear regression they accounted for 29.5% of the variability in fibrosis rate (r²=0.295). METAVIR and Ishak scores were highly correlated (r=0.935, p<0.0001). In 137 patients who had two biopsies, the predicted probability for an increase of 1 on the fibrosis score was too low to assess linearity.

Conclusions: Demographic features account for a minority of fibrosis rate variability. The Ishak and METAVIR scoring systems are equivalent. Linearity of fibrosis progression cannot be assessed in biopsies only a few years apart.

Keywords: hepatitis C; biopsy; fibrosis; natural history

Abbreviations: HCV, hepatitis C virus

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Digest

Ian Forgacs
Gut 2003 52: 459. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Thursz, M. (2007). Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection. Gut 56: 613-614 [Full Text]  
• Grieve, R, Roberts, J, Wright, M, Sweeting, M, DeAngelis, D, Rosenberg, W, Bassendine, M, Main, J, Thomas, H (2006). Cost effectiveness of interferon {alpha} or peginterferon {alpha} with ribavirin for histologically mild chronic hepatitis C. Gut 55: 1332-1338 [Abstract] [Full Text]  
• Gee, I, Alexander, G (2005). Liver transplantation for hepatitis C virus related liver disease. Postgrad. Med. J. 81: 765-771 [Abstract] [Full Text]  
• Richardson, M M, Powell, E E, Barrie, H D, Clouston, A D, Purdie, D M, Jonsson, J R (2005). A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. J. Med. Genet. 42: e45-e45 [Abstract] [Full Text]  
• Wright, M, Goldin, R, Hellier, S, Knapp, S, Frodsham, A, Hennig, B, Hill, A, Apple, R, Cheng, S, Thomas, H, Thursz, M (2003). Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 52: 1206-1210 [Abstract] [Full Text]